EUCTR2018-003365-34-GB进行中（未招募）1 期
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Primary Biliary Cholangitis Who Have an Inadequate Response or are Intolerant to UDCA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Subjects will be eligible for randomization only if they meet all of the
- •following criteria within the screening period, which is =49 days prior to randomization, unless
- •specifically defined:
- •Type of Patient and Disease Characteristics
- •[1] Male or female patients who are at least 18 years of age.
- •[2] Have a diagnosis of PBC (consistent with American Association for
- •the Study of Liver Disease [AASLD] and European Association for Study of the Liver [EASL]
- •Practice Guidelines; [Lindor 2009; EASL 2017]), as demonstrated by the presence of at least 2 of the following 3 diagnostic factors:
- •? History of elevated ALP levels for at least 6 months
- •? Positive antimitochondrial antibodies titer
- •? Liver biopsy consistent with PBC
- •[3] Have ALP =1.67 x ULN but <6 x ULN
- •[4] Taking UDCA for at least 52 weeks (stable dose for at least 12 weeks) prior to Visit 3
- •(Week 0), or have previously taken, but are intolerant (in the opinion of the investigator) to UDCA and have not received UDCA for at least 12 weeks
- •prior to Visit 3 (Week 0).
- •Patient Characteristics
- •[5] Nonpregnant, nonbreastfeeding female patients of childbearing
- •a. Patients who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their
- •preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relationships with the opposite sex during the entirety of the study and for at least 1 week following the last dose of investigational product.
- •Total abstinence is defined as refraining from intercourse during the entirety of the study and for at least 1 week following the last dose of
- •investigational product. Periodic abstinence such as calendar, ovulation, symptothermal, postovulation methods, and withdrawal are not acceptable methods of contraception b. Otherwise, patients must agree to use for the entirety of the study and for at least 1 week following the last dose of investigational product, 2
- •effective methods of contraception, where at least 1 form is highly effective (such as combination oral contraceptives, implanted contraceptives or
- •intrauterine devices). Effective contraception (such as male or female condoms with
- •spermicide, diaphragms with spermicide or cervical sponges) may be used as the second therapy. Barrier protection methods without concomitant
- •use of a spermicide are not a reliable or acceptable method.
- •Female patients of nonchildbearing potential may participate without requirements for contraception. This includes female patients who are:
- •a. Infertile due to surgical sterilization (hysterectomy, bilateral
- •oophorectomy,
- •or tubal ligation), congenital anomaly such as mullerian agenesis; or
- •b. Postmenopausal – defined as either
- •i. A woman at least 50 years of age with an intact uterus, not on
- •hormone therapy, who has had either
- •1. Cessation of menses for at least 1 year,
排除标准
- •Medical Conditions
- •[7] History or presence of other concomitant liver diseases including:
- •a. Hepatitis C virus (HCV) infection (hepatitis C antibody-positive and HCV ribonucleic acid [RNA] positive). ? Note: Patients who have documented anti-HCV treatment for a past HCV infection AND are HCV RNA-negative with a sustained viral response may be enrolled in the study.
- •b. Hepatitis B virus (HBV) infection defined as:
- •? positive for hepatitis B surface antigen (HBsAg), or
- •? positive for hepatitis B core antibody (HBcAb)
- •c. Primary sclerosing cholangitis
- •d. Alcoholic liver disease
- •e. Autoimmune liver disease other than PBC, such as overlap hepatitis
- •f. Nonalcoholic steatohepatitis
- •g. Gilbert's syndrome
- •[8] Presence of clinical complications of PBC or clinically significant hepatic decompensation, including:
- •a. Liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score = 15
- •b. Portal hypertension with complications, including known gastric or esophageal varices, ascites, history of variceal bleeds or related therapeutic
- •or prophylactic interventions (e.g., beta blockers, insertion of variceal bands or transjugular intrahepatic portosystemic shunt), or hepatic
- •encephalopathy
- •c. Cirrhosis, including history or presence of one or more of the
- •following: spontaneous bacterial peritonitis, hepatocellular carcinoma
- •d. Hepatorenal syndrome (type I or II)
- •[9] Have an estimated glomerular filtration rate (eGFR) based on the most recent available serum creatinine of <90 mL/min/1.73 m2.
- •[10] Have screening electrocardiogram (ECG) abnormalities that in the opinion of the investigator or the sponsor are clinically significant and indicate an unacceptable risk for the patient's participation in the study.
研究者
相似试验
进行中（未招募）
1 期
A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA.MedDRA version: 20.0Level: PTClassification code 10008604Term: CholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersPrimary Biliary CholangitisEUCTR2018-003365-34-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER2
进行中（未招募）
1 期
Investigation on the effect and tolerability of erenumab in trigeminal neuralgiaMedDRA version: 20.0Level: PTClassification code 10044652Term: Trigeminal neuralgiaSystem Organ Class: 10029205 - Nervous system disordersTrigeminal neuralgiaEUCTR2019-000848-95-DKDansk Hovedpine Center, Neurologisk Klinik, Rigshospitalet - Glostrup80
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group, Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia - NDBenign Prostatic HyperplasiaEUCTR2006-001958-27-ITELI LILLY1,265
进行中（未招募）
1 期
A randomized study to evaluate the efficacy of Tocilizumab to induce Remission and to spare Glucocorticoids in subjects with new-onset Polymyalgia Rheumatica.Polymyalgia rheumaticaPolymyalgia rheumatica is an inflammatory rheumatic disease that occurs primarily in the elderly with a peak incidence around 70 years of age. It is clinically characterized by shoulder girdle and hip pain and stiffness which impair raising arms and rising from a chair.EUCTR2016-004990-42-ATMedizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Rheumatologie36
进行中（未招募）
1 期
Study of a new therapeutic agent used to treat portopulmonary hypertensioPortopulmonary hypertensionMedDRA version: 20.0Level: PTClassification code 10067281Term: Portopulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-004624-21-CZACTELION Pharmaceuticals Ltd.84